Arca
Skip to content

Ileus

Drug research and approvals for ileus: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 17, 2026, 28 studies of ileus are recruiting on ClinicalTrials.gov, and Health Canada has authorized 0 drug trials for it since 2013.

  • Recruiting worldwide: 28
  • Trials authorized in Canada: 0
  • FDA orphan approvals: 0
  • EU medicines: 0

Recruiting Now

Newest start dates first, of 28 recruiting on ClinicalTrials.gov ↗

Drug Pipeline

10 in phase 3, 9 in phase 2, 2 in phase 1 or earlier; from ChEMBL's drug indications, furthest stage reached for this condition
Alvimopan
Phase 3 Mu opioid receptor antagonist
Tranexamic acid
Phase 3 Plasminogen inhibitor
Methylnaltrexone
Phase 3 Mu opioid receptor antagonist
Ulimorelin
Phase 3 Ghrelin receptor agonist
Lidocaine
Phase 3 Sodium channel alpha subunit blocker
Dextrose
Phase 3
Bupivacaine
Phase 3 Sodium channel protein type IV alpha subunit blocker
Hydromorphone
Phase 3 Mu opioid receptor agonist
Naloxegol
Phase 3 Mu opioid receptor antagonist
Mosapride
Phase 3 Serotonin 3 (5-HT3) receptor antagonist
TU-100
Phase 2
Pyridostigmine
Phase 2 Acetylcholinesterase inhibitor
Caffeine
Phase 2 Adenosine receptor antagonist
Prucalopride
Phase 2 Serotonin 4 (5-HT4) receptor agonist
Asimadoline
Phase 2 Kappa opioid receptor agonist
Diatrizoic acid
Phase 2 Diagnostic agent
Water
Phase 2
Ipamorelin
Phase 2
Dexamethasone
Phase 1 Glucocorticoid receptor agonist
Oxygen
Phase 1 Essential for cellular homeostasis

How Its Trials Ended

119 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 34 whose ending is known, 41% met their primary endpoint, 12% missed it and 47% stopped early.

  • Completed, result not reported4941%
  • Status unknown2319%
  • Met its primary endpoint1412%
  • Ongoing1311%
  • Stopped: other or unclear87%
  • Missed its primary endpoint43%
  • Stopped: enrollment or feasibility43%
  • Stopped: sponsor or business decision33%
  • Stopped: lack of efficacy11%

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.